xRead - September 2022

Wise et al.

Page 255

1453. Serra HA, Alves O, Rizzo LF, Devoto FM, Ascierto H. Loratadine-pseudoephedrine in children with allergic rhinitis, a controlled double-blind trial. Br J Clin Pharmacol. 1998;45:147–150. [PubMed: 9491827] 1454. Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol. 1997;100:781–788. [PubMed: 9438487] 1455. Bronsky E, Boggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratadine pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol. 1995;96:139–147. [PubMed: 7636050] 1456. Grossman J, Bronsky EA, Lanier BQ, et al. Loratadine-pseudoephedrine combination versus placebo in patients with seasonal allergic rhinitis. Ann Allergy. 1989;63:317–321. [PubMed: 2529798] 1457. Sussman GL, Mason J, Compton D, Stewart J, Ricard N. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104:100–106. [PubMed: 10400846] 1458. Bertrand B, Jamart J, Marchal JL, Arendt C. Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: a double-blind multicentre study. Rhinology. 1996;34:91–96. [PubMed: 8876070] 1459. Grosclaude M, Mees K, Pinelli ME, Lucas M, Van de Venne H. Cetirizine and pseudoephedrine retard, given alone or in combination, in patients with seasonal allergic rhinitis. Rhinology. 1997;35:67–73. [PubMed: 9299654] 1460. Pleskow W, Grubbe R, Weiss S, Lutsky B. Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2005;94:348–354. [PubMed: 15801245] 1461. Chervinsky P, Nayak A, Rooklin A, Danzig M. Efficacy and safety of desloratadine/ pseudoephedrine tablet, 2.5/120 mg two times a day, versus individual components in the treatment of patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2005;26:391–396. [PubMed: 16450574] 1462. Grubbe RE, Lumry WR, Anolik R. Efficacy and safety of desloratadine/pseudoephedrine combination vs its components in seasonal allergic rhinitis. J Investig Allergol Clin Immunol. 2009;19:117–124. 1463. Chiang YC, Shyur SD, Chen TL, et al. A randomized controlled trial of cetirizine plus pseudoephedrine versus loratadine plus pseudoephedrine for perennial allergic rhinitis. Asian Pac J Allergy Immunol. 2006;24:97–103. [PubMed: 17136873] 1464. Chen YA, Chang KP, Lin YS, Hao SP. A randomized, double-blind, parallel-group study to compare the efficacy and safety of a once-daily loratadine-pseudoephedrine combination with that of a twice-daily loratadine-pseudoephedrine combination in the treatment of allergic rhinitis. Eur Arch Otorhinolaryngol. 2007;264:1019–1025. [PubMed: 17464511] 1465. Yau WP, Mitchell AA, Lin KJ, Werler MM, Hernandez-Diaz S. Use of decongestants during pregnancy and the risk of birth defects. Am J Epidemiol. 2013;178:198–208. [PubMed: 23825167] 1466. Hampton LM, Nguyen DB, Edwards JR, Budnitz DS. Cough and cold medication adverse events after market withdrawal and labeling revision. Pediatrics. 2013;132:1047–1054. [PubMed: 24218462] 1467. Moinuddin R, deTineo M, Maleckar B, Naclerio RM, Baroody FM. Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2004;92:73–79. [PubMed: 14756468] 1468. Stubner UP, Toth J, Marks B, Berger UE, Burtin B, Horak F. Efficacy and safety of an oral formulation of cetirizine and prolonged-release pseudoephedrine versus xylometazoline nasal spray in nasal congestion. Arzneimittelforschung. 2001;51:904–910. [PubMed: 11765592] 1469. Wilson A, Dempsey OJ, Sims EJ, Coutie WJ, Paterson MC, Lipworth BJ. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clin Exp Allergy. 2000;30:833–838. [PubMed: 10848901]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.